In an attempt to reorganise its oncology pipeline, MorphoSys has entered into a license agreement with Human Immunology Biosciences (HIBio) to develop and commercialise MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody. The deal, which involves a US$15 M upfront payment and US$1 B in milestones, grants HIBio exclusive worldwide rights to the oncology drugs, with the exception of Greater China for both assets and South Korea for MOR210. The announcement shortly follows MorphoSys’ decision to cease its US-based R&D activities in order to focus in on its most advanced programmes.